Table 5.
Selected checkpoint inhibitors currently being evaluated in patients with NHL.
| Name | Trade Name | Developed by | Structure | Target | First Approval by US FDA for the Treatment of Cancer | Number of Studies in Patients with NHL Registered at ClinicalTrials.gov |
|---|---|---|---|---|---|---|
| Ipilimumab | Yervoy | Bristol-Myers-Squibb | human IgG1 | CTLA-4 | 2011 | 13 |
| Tremelimumab | N/A | AstraZeneca | human IgG2 | CTLA-4 | N/A | 3 |
| Pembrolizumab | Keytruda | Merck | humanized IgG4 | PD-1 | 2014 | 60 |
| Nivolumab | Opdivo | Bristol-Myers-Squibb | human IgG4 | PD-1 | 2014 | 41 |
| Pidilizumab | N/A | Medivation | human IgG1 | PD-1 | N/A | 3 |
| Durvalumab | Imfinzi | AstraZeneca | human IgG1 | PD-L1 | 2020 | 19 |
| Avelumab | Bavencio | Merck, Pfizer | human IgG1 | PD-L1 | 2017 | 9 |
| Atezolizumab | Tenetriq | Roche | humanized IgG1 | PD-L1 | 2016 | 20 |
N/A—not applicable.